In various population-based studies and clinical series, VP reportedly accounted for 2.5% to 5.0% of all cases of parkinsonism 4 . In Brazil, Cardoso et al. 5 reported that VP was present in 4.7% of 338 patients who were followed up in a tertiary care specialized movement disorder unit. In a more recent study, Munhoz et al. 6 diagnosed VP in 3.9% of patients in a large clinically based series of 1,528 patients with parkinsonism. In a community-based survey, called the Bambuí Study, 86 cases of parkinsonism were diagnosed among 1,186 study participants who were aged 64 years or older 7 .
The most frequent causes were Parkinson's disease (PD) and drug-induced parkinsonism. The third most frequent etiology was VP, which was diagnosed in 13 (15.1%) patients; it had a crude prevalence rate of 1.1% (95%CI 0.4-1.8).
The clinical features of VP were assessed by a recent systematic review that aimed to determine the characteristics that distinguish VP from PD 8 . Seven clinical studies were selected and they showed that the mean age at symptom onset was four to ten times higher in patients with VP than in patients with PD. Patients with VP more commonly presented with symmetrical gait difficulties, postural instability, falls, dementia, pyramidal signs, pseudobulbar palsy, and urinary incontinence. Patients with PD were likewise more rigid and tremulous and tended to have more hypokinesia or bradykinesia. Vascular risk factors were more common in VP than in PD. This paper is the first Brazilian case series of VP that aims to provide a clinicoradiological profile of the disease from a university setting outpatient movement disorder clinic.
METHODS

Subjects
This was a cross-sectional study of 17 patients who had a diagnosis of VP and were regularly followed-up in the Movement Disorders Outpatient Clinic of the Hospital das Clínicas of the Federal University of Minas Gerais in Belo Horizonte, Minas Gerais, Brazil. Patients had their diagnosis confirmed by applying the criteria of Zijlmans et al. 3 . They were selected to participate in a structured interview to identify epidemiological and clinical data such as the age and mode of onset of their parkinsonism and dementia; its clinical course; the presence of comorbidities; past medical history (especially in regard to their past cerebrovascular event); family history; use of medication; presence of adverse medication effects; presence of levodopa fluctuations and dyskinesia; presence of visual hallucination; falls; urinary incontinence; freezing of gait (FOG); and difficulties in daily living activities. A retrospective medical chart review was eventually necessary to retrieve missing information.
Patients had to fulfill Zijlmans' probable criteria for VP, which were (1) parkinsonism (defined as bradykinesia accompanied by at least one of following: rest tremor, muscular rigidi ty, or postural instability); (2) cerebrovascular disease, defined by evidence of relevant cerebrovascular disease, as indicated by brain imaging computed tomography (CT) or magnetic resonance imaging (MRI), or by the presence of focal signs or symptoms that are consistent with stroke; (3) a relationship between the parkinsonism and cerebrovascular disease, as ascertained by (i) an acute or delayed progressive onset with infarcts in or near areas that can increase basal ganglia motor output (e.g. the external segment of the globus pallidus or subs tantia nigra pars compacta) or a direct decrease in the thalamocortical drive (e.g. ventrolateral nucleus of the thalamus, large frontal lobe infarct) -the parkinsonism consists of a contralateral bradykinetic rigid syndrome or a shuffling gait that develops within one year after a stroke; or as ascertained by (ii) an insidious onset of parkinsonism with extensive subcortical white matter lesions, bilateral symptoms at onset, and the early onset of a shuffling gait or cognitive dysfunction.
Because of the heterogeneity of clinical pictures of VP, we used the Fénelon and Houéto 9 classification of VP to divide it into four types, based on the clinical manifestation: (1) VP manifesting in a manner identical to PD; (2) unilateral parkinsonism after a contralateral vascular lesion; (3) "atypical" parkinsonian syndromes; and (4) "parkinsonian" gait di sorders. Three categories were considered in regard to their clinical course: (1) rapidly progressive (i.e. worsening of symptoms to a nadir in less than a year after its onset); (2) stable; and (3) slowly progressive (i.e. worsening of symptoms to a nadir more than a year after its onset).
Other inclusion criteria were current use of levodopa and a Hoehn-Yahr stage of 1 to 4. Exclusion criteria included the following: 1. Evident and documented orthopedic, rheumatologic, or spinal cord disease that significantly impaired the application of motor scales and that may have otherwise posed challenges to the diagnosis; 2. Evident and documented visual abnormalities that significantly impaired the application of cognitive scales; 3. Past medical history of brain trauma or tumor; 4. Hoehn-Yahr stage 5 (i.e. wheelchair bound or bedbound), so that the patient is unable to perform the tests; 5. Diagnostic uncertainty from the medical charts review; 6. Inability of the patient to undergo neuroimaging; 7. Missing data or lack of adequate information from the patient and family; and 8. Patient's refusal to give written consent.
Scales and tests
The first version of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was used in the analysis of non-motor and motor symptoms of the disease 10, 11 . Patients were examined according to Part III of the scale in the early morning after a 12-hour interruption from levodopa use (i.e. the "OFF" period). Immediately afterwards, the FOG scale by Giladi et al. 12, 13 , which was recently translated into Portuguese 14 , was applied to all patients during the "OFF" period. Patients were instructed to use their re gular diurnal dose of levodopa and were evaluated with the aforementioned scales after an hour. Response to levodopa was determined by this test -named the "practically defined off " test -initially described by the Core Assessment Program for Intracerebral Transplantations (CAPIT) 15, 16 , in which patients had a 12-hour interruption in levodopa use. Response was based on the percentage of reduction in the MDS-UPDRS scale 17 and the Hoehn-Yahr stage. Cognitive assessment was made by the Mini-Mental State Examination (MMSE) 18, 19 , the Frontal Assessment Battery (FAB) 20, 21 , and the Executive Interview (EXIT25) 22, 23 . Functional activities of daily living were assessed by the Pfeffer 24 scale and the Katz scale 25 . Probable vascular dementia was diagnosed based on the criteria of the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-AIREN) 26 and supported by the Hachinski score 27 . A 1.0 Tesla brain MRI was performed in all patients and fluid-attenuated inversion recovery (FLAIR), and T2-and T1-weighted sequences were used to measure the white matter burden by using the Fazekas scale 28 .
Cut-off values
Lower limb parkinsonism predominance was determi ned by a two-point difference between the upper limb and lower limb scores of bradykinesia, rigidity, and/or postural instability from Part III of the MDS-UPDRS scale. The pre sence of FOG was assessed by Item 14 of the MDS-UPDRS scale and by one or more points of the Giladi FOG scale, Item 3. Responders to the levodopa diurnal dose were patients who reached a percentage reduction exceeding 25% in Part III of the UPDRS 17 . The MMSE scores were correla ted to the number of years of schooling. Patients were considered cognitively impaired when they scored less than 21 points ( for 1-3 years of schooling), less than 24 points ( for 4-7 years of schooling), and less than 26 points ( for 8 years or more years of schooling) 19 . The FAB scores (up to 18 points) were also subjected to variability in accordance with the formal years of schooling. Patients were considered exe cutively dysfunctional when they scored less than 8.6 points ( for 1-3 years of schooling), less than 10.1 points ( for 4-7 years of schooling), less than 11.6 points ( for 8-11 years of schooling), and less than 13 points ( for more than 12 years of schooling) 21 . Patients were assessed by the EXIT25 scale (up to 50 points) to determine if they had executive dysfunction. Points on this scale also varied in accordance with the formal years of schooling: 5.1 points ( for 1-4 years of schooling), 3.3 points ( for 5-8 years of schooling) and 2.9 points ( for more than 8 years of schooling) 23 .
Statistics and ethics
Statistical analysis consisted of descriptive univariate analysis (mean±standard deviation) by using SPSS 20.1 softwa re (IBM Corporation Software Group, USA). The study was approved by the Ethics Committee of the Federal University of Minas Gerais (Belo Horizonte, Minas Gerais, Brazil). All procedures were performed with adequate understanding and written consent of the patients or their relatives (whenever necessary).
RESULTS
Ten patients (58.8%) were male and the mean ± standard deviation (SD) age of the whole sample was 75.8±10.1 years (expressed as the mean±standard deviation [SD] ). The mean number of years of formal schooling was 2.9±2.5 years. All patients had arterial hypertension; 10 (58.8%) patients had dyslipidemia; and eight (47.0%) patients had type 2 diabetes. Three (17.6%) patients used tobacco and alcohol. Thirteen (76.4%) patients had a previous history of lacunar stroke and developed parkinsonism within less than a month from the event. The remaining patients had an insidious onset of parkinsonism with extensive subcortical white matter disease in areas adjacent to the basal ganglia and thalamus. The mean age of onset of parkinsonism was 72.2±10.0 years. Eight (47.0%) patients had a rapidly progressive course of symptoms, whereas five (29.4%) patients had stable symptoms and four (23.5%) patients had slowly progressive symptoms. According to the aforementioned Fénelon and Houéto 9 classification, we encountered patients from all groups, except the one patient in which the VP manifes ted in a manner identical to PD. All patients had been u sing levodopa for a mean period of 2.9 years and the mean dose was 530.9±218.2 mg/day. No patient reported the u sual complications of levodopa use such as dyskinesia and fluctuation.
The most common symptoms were urinary incontinence (88.2%), lower limb parkinsonism with falls and FOG (82.3%), and pyramidal signs (76.4%). The mean MDS-UPDRS total score was 72.5±21.6 points; the MDS-UPDRS Part III score was 46.3±8.0 points; the Giladi's FOG score was 13.7±6.7 points; and the Hoehn-Yahr stage score was 3.3±0.9 points. The "practically-defined off " test determined a mean 6.9±4.8 point reduction in the UPDRS scale and a mean 5.8±4.4 point reduction in UPDRS Part III. There was no change in HoehnYahr stages between periods when patients were examined when "ON" and when "OFF" levodopa.
Cognitive assessment by the MMSE, FAB, and EXIT25 scales resulted in mean values of 16.2±5.8 points, 3.8±3.5 points, and 35.4±11.5 points, respectively. Twelve (70.5%) patients fulfilled the criteria for probable vascular dementia and had a mean Hachinski score of 9.4±2.2 points. The mean Pfeffer's Functional Activities Questionnaire score was 2.6±1.4 points and the mean Katz Index of Independence in Activities of Daily Living score was 15.7±7.0 points.
Except for one patient who had a strategic lacunar infarct in the contralateral substantia nigra and two patients with only periventricular white matter lesions, most (58.8%) patients had multiple lacunar infarcts and 23.5% of the patients had extensive white matter disease. The mean Fazekas scale of white matter burden was 2.47±0.7 points.
DISCUSSION
In this case series, VP was mostly characterized by lower limb parkinsonism with frequent FOG and falls, urinary incontinence, pyramidal signs, and executive dysfunction with concomitant probable vascular dementia. There was no response to levodopa and most patients had multiple infarcts or an extensive white matter disease burden, as indicated by brain MRI. The onset of the movement disorder occurred in patients who were in their seventies and symptom onset was preceded by an overt cerebrovascular event -mostly lacunar -in most patients.
Because of prognostic and therapeutic implications, the most important consideration when making a diagnosis of VP is differentiating it from PD 4 . Based on a systematic review of seven clinical studies and 16 other comparative studies (which included an assessment of imaging data), patients with VP were older, had a shorter duration of the illness, presented with symmetrical gait difficulties, and were less res ponsive to levodopa. They were also more prone to postural instability, falls, and dementia. Pyramidal signs, pseudobulbar palsy, and urinary incontinence were also common. By contrast, patients with PD presented with upper limb asymmetrical rest tremor or bradykinesia and they had a pro minent response to levodopa. Vascular risk factors were more common in patients with VP than in patients with PD 8 . Table 1 summarizes the seven clinical studies of VP in comparison to PD. On brain MRI, the diagnosis of VP must be supported by the presence of diffuse white matter lesions and/or strategic subcortical infarcts. The exact pathophysiological mechanisms leading to VP are unknown, although diffuse white matter lesions may damage the net thalamocortical loop, thereby decreasing the ultimate influence of the basal ganglia on higher centers of motor planning and execution. All the same, strategic infarcts would cause parkinsonism by disrupting the putamino-pallido-thalamic loop 1, 35 . Notwithstanding the clinical variability, neuroimaging is also problematic. Infarctions of the basal ganglia and deep white matter occur very frequently in the elderly who do not have parkinsonism, and patients with pathologically confirmed PD may present with vascular lesions as incidental findings. Hence, a large proportion of patients with late-onset PD have some white matter changes on brain scans that may prompt physicians to incorrectly diagnose VP 9, 36 . The association bet we en comorbid white matter disease and PD most consisten tly manifests as an impairment of axial motor symptoms and executive functions; therefore a subtype of a more rapidly evol ving and aggressive PD could misdirect physicians to a diag nosis of VP 37 . Most specialists would argue that differentiation would be possible by means of assessing levodopa responsiveness and olfaction. To further complicate matters, Zijlmans et al. 38 have reported good or excellent responses to levodopa in 12 of 17 patients with pathologically confirmed VP. The use of the University of Pennsylvania Smell Test may be a helpful discriminator since olfaction is appa rently preserved in patients with VP, whereas 80% of patients with PD are hyposmic 39 . This uncertainty and difficulty in diagnosing parkinsonian syndrome is exemplified by the study of Horvath et al. 40 who investigated the clinical accuracy of diagnosis with the pa thological gold standard method. The overall diagnostic accuracy in their sample was 63.4%. For patients with PD, the diagnostic accuracy was 71.2% for the entire study pe riod and increased for the ensuing decades, and reached 85.7% in the last decade. Clinical misdiagnoses included nine cases of unspecified parkinsonian syndrome, one case of postencephalitic parkinsonism, one case of progressive supranuclear palsy, three cases of VP, and one case of drug-induced parkinsonism.
This paper presented a rather typical case series of VP in which the patients had their diagnosis confirmed many times by follow-up consultations with movement disorders specialists. Our case series showed a high number of concomitant probable vascular dementia diagnosis. Unlike in patients with PD, cognitive decline can be present in VP at presentation or can develop early in the course of the disease. The dementia is usually subcortical, manifesting as dysexecutive syndrome with impairment of attention, planning, judgment, goal-directed behavior, abstract thin king, verbal fluency, and apathy. Concomitant cognitive decline or dementia has already been reported by other authors 3, 41, 42 . In the Bambuí study 7 , eight (61.5%) of 13 patients with VP presented with the concomitant diagnosis of vascular dementia. In a case series of 28 cases of pathologically confirmed VP, Glass et al. 43 found concomitant dementia in 39% of the patients.
In conclusion, this case series provides a clinical and neuroimaging profile of VP. All patients had arterial hypertension and they were in their seventies when symptoms appeared. The clinical picture comprised lower limb parkinsonism with FOG and falls, pyramidal signs, executive dysfunction, and poor levodopa responsiveness. Most patients developed concomitant probable vascular dementia and had multiple infarcts or an extensive white matter burden on brain MRI. Physicians should keep this profile in mind when dealing with parkinsonism in the elderly population, especially in people with a history of stroke. 
